SCNI CEO Amir Reichman Buys 400,000,000 Shares

Amir Reichman, the Chief Executive Officer of SCNI, made a notable insider purchase on June 16, 2026, acquiring 400 million shares of the company. This move, not part of a pre-planned trading program, may signal confidence in SCNI's future prospects. The transaction did not specify a purchase price or total value.

Insider Buying and Selling at Scinai Immunotherapeutics Ltd.

On June 16, 2026, SCNI's CEO, Amir Reichman, bought 400 million shares in an unplanned transaction, reinforcing his commitment to the company. Additionally, Mark Germain, also made an insider purchase, acquiring 120 million shares on the same day.

Other Institutional Activity in SCNI

While Amir Reichman increased his stake, several institutional investors adjusted their positions in SCNI. XTX Topco Ltd reduced its holdings by 3,253 shares, ending with 24,041 shares valued at approximately $13,283. UBS Group AG also cut its position by 829 shares, holding 919 shares worth about $524. Northwestern Mutual Wealth Management Co and Citadel Advisors LLC exited their positions entirely, selling all their shares.

Scinai Immunotherapeutics Ltd. Stock Down 79.3%

Shares of SCNI traded around $0.32, reflecting the market's valuation of the company. The recent insider buying activity might influence investor sentiment and potentially impact the stock's performance.

Bottom Line

Amir Reichman's significant insider purchase of 400 million shares in SCNI on June 16, 2026, highlights a strong vote of confidence from the company's leadership. While some institutional investors reduced or exited their positions, this insider activity could be a positive signal for the market. As always, it's important to remember that insider transactions are reported after the fact and may not indicate future stock performance.